New drug for moderate to severe lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 or older (18 in China).
- You must have been diagnosed with lupus (SLE) for at least 6 months.
- Your lupus must be moderate or severe, with current symptoms in at least 2 organ systems or one severe symptom.
- You must have lab evidence of lupus activity, like certain antibodies or low complement levels.
- You must be on a stable dose of standard lupus medications (such as antimalarials, steroids, or immunosuppressants).
- You cannot have serious infections, recent live vaccines, or certain cancers in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.